@FierceMedDev: ICYMI Friday: Abiomed swings to loss on legal costs. Story | Follow @FierceMedDev
@MarkHFierce: ConforMIS, armed with $167.7M expanded series E, plots global marketing expansion. Report | Follow @MarkHFierce
@DamianFierce: Gore prevailed over St. Jude in a patent lawsuit over heart plugs. News | Follow @DamianFierce
@MichaelGFierce: Halozyme regrouping after ViroPharma trial flop. More from FierceDrugDelivery.com | Follow @MichaelGFierce
> Sequenom ($SQNM) won a clinical lab permit from the New York State Department of Health, only the second non-invasive prenatal test provider to do so after Illumina's ($ILMN) Verinata Health. More
> Cernostics has raised $1.4 million to develop a test to determine patients' risk of developing esophageal cancer. Story
> The New York Times takes an in-depth look at hip replacements around the world, charting pricing differences between the U.S. and Europe and the booming industry that built Zimmer ($ZMH), Biomet and other giants. Feature
> Alere ($ALR) is just two days away from a shareholder vote that could change the direction of the company, and management sent a final letter to investors urging them to elect its board nominees. Letter
> Life Technologies ($LIFE) has teamed up with RainTree Oncology Services to make the latest advances in molecular diagnostics more available to patients around the world. News
Biotech News
@FierceBiotech: Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. News | Release | Follow @FierceBiotech
@JohnCFierce: India revokes divisional patents on Herceptin. These emerging markets sure can be quite nettlesome. Report | Follow @JohnCFierce
@RyanMFierce: Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More from FierceBiotechIT | Follow @RyanMFierce
> The FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report
> Bayer aims at hot cancer immunotherapy race with $540M R&D deal. News
Pharma News
@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma
@EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter exemplify very real challenges. Article | Follow @EricPFierce
@CarlyHFierce: Roche signs agreement to make drug that prevents blindness in HIV patients available in developing nations. Release | Follow @CarlyHFierce
> J&J slapped with HHS subpoena on Nucynta marketing. Story
> India hits Roche's Herceptin in latest blow to Big Pharma patents. More
> Drug shortage complicates execution schedule for death penalty leader Texas. Article
CRO News
> Charles River boosts sales as charges drag profits. Article
> INC expands in Japan as local market soars. Story
> Clinipace reaches into the north with CRO partnership. Item
> Quintiles posts flat revenue as charges swallow profits. Report
> Covance swings to profit despite tough early-phase market. More
> KKR buying RPS, planning to merge it with PRA. Article
Biotech IT News
> China pharma R&D drives expanded use of Medidata software. News
> Computer-aided Compugen crashes cancer immunotherapy party with Bayer deal. More
> Accelrys to ax 80 jobs after drop in quarterly profits. News
> Battle against breast cancer goes open source. Story
> Ex-Yahoo CEO backs genomics big data startup Bina. Article